Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial

Strojan, Primoz; Plavc, Gaber; Kokalj, Marko; Mitrovic, Goran; Blatnik, Olga; Lezaic, Luka; Socan, Aljaz; Bavec, Aljosa; Tesic, Natasa; Hartman, Katrina; Svajger, Urban

doi:10.2478/raon-2023-0052

Abstract

Background

Xerostomia is a common side effect of radiotherapy in patients with head and neck tumors that negatively affects quality of life. There is no known effective standard treatment for xerostomia. Here, we present the study protocol used to evaluate the safety and preliminary efficacy of allogeneic mesenchymal stromal stem cells (MSCs) derived from umbilical cord tissue.

Patients and methods

Ten oropharyngeal cancer patients with post-radiation xerostomia and no evidence of disease recurrence 2 or more years after (chemo)irradiation (intervention group) and 10 healthy volunteers (control group) will be enrolled in this nonrandomized, open-label, phase I exploratory study. MSCs from umbilical cord tissue will be inserted under ultrasound guidance into both parotid glands and both submandibular glands of the patients. Toxicity of the procedure will be assessed according to CTCAE v5.0 criteria at days 0, 1, 5, 28, and 120. Efficacy will be assessed by measuring salivary flow and analyzing its composition, scintigraphic evaluation of MSC grafting, retention, and migration, and questionnaires measuring subjective xerostomia and quality of life. In addition, the radiological, functional, and morphological characteristics of the salivary tissue will be assessed before, at 4 weeks, and at 4 months after the procedure. In the control group subjects, only salivary flow rate and salivary composition will be determined.

Discussion

The use of allogeneic MSCs from umbilical cord tissue represents an innovative approach for the treatment of xerostomia after radiation. Due to the noninvasive collection procedure, flexibility of cryobanking, and biological advantages, xerostomia therapy using allogeneic MSCs from umbilical cord tissue may have an advantage over other similar therapies.

References

Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, et al. The impact of cancer incidence and stage on optimal utilization of radiotherapy: methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol 2015; 116: 45–50. doi: 10.1016/j.radonc.2015.04.021
Open DOI Search in Google Scholar Back to article
Peng X, Wu Y, Brouwer U, van Vliet T, Wang B, Demaria M, et al. Cellular senescence contributes to radiation-induced hyposalivation by affecting the stem/progenitor cell niche. Cell Death Dis 2020; 11: 854. doi: 10.1038/s41419-020-03074-9
Open DOI Search in Google Scholar Back to article
Siddiqui F, Movsas B. Management of radiation toxicity in head and neck cancers. Semin Radiat Oncol 2017; 27: 340–9. doi: 10.1016/j.semradonc.2017.04.008
Open DOI Search in Google Scholar Back to article
Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004; 26: 796–807. doi: 10.1002/hed.20045
Open DOI Search in Google Scholar Back to article
Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127–36. doi: 10.1016/S1470-2045(10)70290-4
Open DOI Search in Google Scholar Back to article
Nuyts S, Bollen H, Ng SP, Corry J, Eisbruch A, Mendenhall WM, et al. Proton therapy for squamous cell carcinoma of the head and neck: early clinical experience and current challenges. Cancers 2022; 14: 2587. doi: 10.3390/cancers14112587
Open DOI Search in Google Scholar Back to article
Chen D, Chen X, Chen X, Jiang N, Jiang L. The efficacy of positioning stents in preventing oral complications after head and neck radiotherapy: a systematic literature review. Radiat Oncol 2020; 15: 90. doi: 10.1186/s13014-020-01536-0
Open DOI Search in Google Scholar Back to article
Riley P, Glenny AM, Hua F, Worthington HV. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy. Cochrane Database Syst Rev 2017; 7: CD012744. doi: 10.1002/14651858.CD012744
Open DOI Search in Google Scholar Back to article
Sood AJ, Fox NF, O’Connell BP, Lovelace TL, Nguyen SA, Sharma AK, et al. Salivary gland transfer to prevent radiation-induced xerostomia: a systematic review and meta-analysis. Oral Oncol 2014; 50: 77–83. doi: 10.1016/j.oraloncology.2013.10.010
Open DOI Search in Google Scholar Back to article
Strojan P, Hutcheson KA, Eisbruch A, Beitler JJ, Langendijk JA, Lee AWM, et al. Treatment of late sequelae after radiotherapy for head and neck cancer. Cancer Treat Rev 2017; 59: 79–92. doi: 10.1016/j.ctrv.2017.07.003
Open DOI Search in Google Scholar Back to article
Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 2008; 26: 3770–6. doi: 10.1200/JCO.2007.14.6647
Open DOI Search in Google Scholar Back to article
Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726–36. doi: 10.1038/nri2395
Open DOI Search in Google Scholar Back to article
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–7. doi: 10.1080/14653240600855905
Open DOI Search in Google Scholar Back to article
Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif 2020; 53: e12712. doi: 10.1111/cpr.12712
Open DOI Search in Google Scholar Back to article
Li N, Hua J. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life 2017; 74: 2345–60. doi: 10.1007/s00018-017-2473-5
Open DOI Search in Google Scholar Back to article
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–43. doi: 10.1182/blood.v99.10.3838
Open DOI Search in Google Scholar Back to article
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389–97. doi: 10.1097/01.TP.0000045055.63901.A9
Open DOI Search in Google Scholar Back to article
Roncarolo MG, Gregori S, Bacchetta R, Battaglia M. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. In: Fillatreau S, O’Garra A, editors. Interleukin-10 in health and disease. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 39–68. doi: https://doi.org/10.1007/978-3-662-43492-5
Search in Google Scholar Back to article
Rasmusson I, Ringden O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208–13. doi: 10.1097/01.TP.0000082540.43730.80
Open DOI Search in Google Scholar Back to article
Angoulvant D, Clerc A, Benchalal S, Galambrun C, Farre A, Bertrand Y, et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004; 41: 469–76. PMID: 15299278
Search in Google Scholar Back to article
Zha K, Li X, Yang Z, Tian G, Sun Z, Sui X, et al. Heterogeneity of mesenchymal stem cells in cartilage regeneration: from characterization to application. NPJ Regen Med 2021; 6: 14. doi: 10.1038/s41536-021-00122-6
Open DOI Search in Google Scholar Back to article
Cottle C, Porter AP, Lipat A, Turner-Lyles C, Nguyen J, Moll G, et al. Impact of cryopreservation and freeze-thawing on therapeutic properties of mesenchymal stromal/stem cells and other common cellular therapeutics. Curr Stem Cell Rep 2022; 8: 72–92. doi: 10.1007/s40778-022-00212-1
Open DOI Search in Google Scholar Back to article
Krampera M, Le Blanc K. Mesenchymal stromal cells: putative microenviron-mental modulators become cell therapy. Cell Stem Cell 2021; 28: 1708–25. doi: 10.1016/j.stem.2021.09.006
Open DOI Search in Google Scholar Back to article
National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, 2017. [cited 2023 Apr 14]. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
Search in Google Scholar Back to article
Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 1982; 61: 1158–62. doi: 10.1177/00220345820610100901
Open DOI Search in Google Scholar Back to article
Goličnik M, Bavec A. Evaluation of the paraoxonase-1 kinetic parameters of the lactonase activity by nonlinear fit of progress curves. J Enzyme Inhib Med Chem 2020; 35: 261–4. doi: 10.1080/14756366.2019.1695792
Open DOI Search in Google Scholar Back to article
Petrič B, Goličnik M, Bavec A. iFIT: an automated web tool for determining enzyme-kinetic parameters based on the high-curvature region of progress curves. Acta Chim Slov 2022; 69: 478–82. doi: 10.17344/acsi.2022.7359
Open DOI Search in Google Scholar Back to article
Petrič B, Redenšek Trampuž S, Dolžan V, Gregorič Krambergar M, Trošt M, Makarović N, et al. Investigation of paraoxonase-1 genotype and enzyme-kinetic parameters in the context of cognitive impairment in parkinson's disease. Antioxidants 2023; 12: 399. doi: 10.3390/antiox12020399
Open DOI Search in Google Scholar Back to article
Pai S, Ghezzi EM, Ship JA. Development of a Visual Analogue Scale questionnaire for subjective assessment of saliveary dysfunction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 311–6. doi: 10.1067/moe.2001.111551
Open DOI Search in Google Scholar Back to article
Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-spearing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 695–704. doi: 10.1016/s0360-3016(01)01512-7
Open DOI Search in Google Scholar Back to article
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring manual. 3rd edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001.
Search in Google Scholar Back to article
Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013; 14: 17986–8001. doi: 10.3390/ijms140917986
Open DOI Search in Google Scholar Back to article
Primorac D, Molnar V, Matisic V, Hudetz D, Jelec Z, Rod E, et al. Comprehensive review of knee osteoarthritis pharmacological treatment and the latest professional societies’ guidelines. Pharmaceuticals 2021; 14: 205. doi: 10.3390/ph14030205
Open DOI Search in Google Scholar Back to article
Lim JY, Ra JC, Shin IS, Jang YH, An HY, Choi JS, et al. Systemic transplantation of human adipose tissue-derived mesenchymal stem cells for the regeneration of irradiation-induced salivary gland damage. PLoS One 2013; 8: e71167. doi: 10.1371/journal.pone.0071167
Open DOI Search in Google Scholar Back to article
Lim JY, Yi T, Choi JS, Jang YH, Lee S, Kim HJ, et al. Intraglandular transplantation of bone marrow-derived clonal mesenchymal stem cells for amelioration of post-irradiation salivary gland damage. Oral Oncol 2013; 49: 136–43. doi: 10.1016/j.oraloncology.2012.08.010
Open DOI Search in Google Scholar Back to article
Andrzejewska A, Lukomska B, Janowski M. Concise review: mesenchymal stem cells: from roots to boost. Stem Cells 2019; 37: 855–64. doi: 10.1002/stem.3016
Open DOI Search in Google Scholar Back to article
Grønhøj C, Jensen DH, Vester-Glowinski P, Jensen SB, Bardow A, Oliveri RS, et al. Safety and efficacy of mesenchymal stem cells for radiation-induced xerostomia: a randomized, placebo controlled phase 1/2 trial (MESRIX). Int J Radiat Oncol Biol Phys 2018; 101: 581–92. doi: 10.1016/j.ijrobp.2018.02.034
Open DOI Search in Google Scholar Back to article
Lynggaard CD, Gronhoj C, Jensen SB, Christensen R, Specht L, Andersen E, et al. Long-term safety of treatment with autologous mesenchymal stem cells in patients with radiation-induced xerostomia: primary results of the MESRIX phase I/II randomized trial. Clin Cancer Res 2022; 28: 2890–7. doi: 10.1158/1078-0432.CCR-21-4520
Open DOI Search in Google Scholar Back to article
Lynggaard CD, Gronhoj C, Christensen R, Fischer-Nielsen A, Melchiors J, Specht L, et al. Intraglandular off-the-shelf allogeneic mesenchymal stem cell treatment in patients with radiation-induced xerostomia: a safety study (MESRIX-II). Stem Cells Transl Med 2022; 11: 478–89. doi: 10.1093/stcltm/szac011
Open DOI Search in Google Scholar Back to article
Lakota J, Dubrovcakova M, Haider KH. Human mesenchymal stem cells: the art to use them in the treatment of previously untreatable. In: Haider KH, editor. Handbook of stem cell therapy. Singapore: Springer Singapore; 2022. p. 1–20. doi: 10.1007/978-981-16-6016-0
Open DOI Search in Google Scholar Back to article
Blitzer GC, Rogus-Pulia NM, Mattison RJ, Varghese T, Ganz O, Chappell R, et al. Marrow-derived autologous stromal cells for the restoration of salivary hypofunction (MARSH): study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer. Cytotherapy 2022; 24: 534–43. doi: 10.1016/j.jcyt.2021.11.003
Open DOI Search in Google Scholar Back to article
Blitzer GC, Glazer T, Burr A, Gustafson S, Ganz O, Meyers R, et al. Marrow-derived autologous stromal cells for the restoration of salivary hypofunction (MARSH): a pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia. Cytotherapy 2023. [Ahead of print]. doi: 10.1016/j.jcyt.2023.07.009
Open DOI Search in Google Scholar Back to article
Moretti P, Hatlapatka T, Marten D, Lavrentieva A, Majore I, Hass R, et al. Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. Adv Biochem Eng Biotechnol 2010; 123: 29–54. doi: 10.1007/10_2009_15
Open DOI Search in Google Scholar Back to article
Bárcia RN, Santos JM, Filipe M, Teixeira M, Martins JP, Almeida J, et al. What makes umbilical cord tissue-derived mesenchymal stromal cells superior immunomodulators when compared to bone marrow derived mesenchymal stromal cells? Stem Cells Int 2015; 2015: 583984. doi: 10.1155/2015/583984
Open DOI Search in Google Scholar Back to article
Kehl D, Generali M, Mallone A, Heller M, Uldry AC, Cheng P, et al. Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. NPJ Regen Med 2019; 4: 8. doi: 10.1038/s41536-019-0070-y
Open DOI Search in Google Scholar Back to article
Doi H, Kitajima Y, Luo L, Yan C, Tateishi S, Ono Y, et al. Potency of umbilical cord blood and Wharton's jelly-derived mesenchymal stem cells for scarless wound healing. Sci Rep 2016; 6: 18844. doi: 10.1038/srep18844
Open DOI Search in Google Scholar Back to article
Grønhøj C, Jensen DH, Glovinski PV, Jensen SB, Bardow A, Oliveri RS, et al. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial. Trials 2017; 18: 108. doi: 10.1186/s13063-017-1856-0
Open DOI Search in Google Scholar Back to article

Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial

Abstract

Background

Patients and methods

Discussion

Paradigm

My account